{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-24-007877","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.538114+00:00","generated_at":"2026-06-03T04:32:20.291595+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alzamend Neuro raises $400K via convertible preferred and short-term note","bullets":["Sold 100 Series B preferred shares and warrants for 100K common shares to Ault Lending for $100K; total $2.1M of $6M facility drawn.","Issued $310K face promissory note (15% interest, $10K OID) to Orchid Finance LLC; matures May 13, 2024.","Note repayment guaranteed by Ault Lending and Milton C. Ault, Vice Chairman of Alzamend.","Proceeds used for working capital; note matures in two weeks, creating near-term repayment risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-24-007877","json":"https://secwatch.observer/filing/0001214659-24-007877.json","markdown":"https://secwatch.observer/filing/0001214659-24-007877.md","text":"https://secwatch.observer/filing/0001214659-24-007877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/g4302428k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:32:20.291595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8ee238505ee7f4f6c3faff4357edc094f6042b6","claim":"Alzamend Neuro, Inc. incurred loan of $310,000 with an accredited investor at fifteen percent (15%) per annum maturing May 13, 2024.","evidence_excerpt":"Effective April 29, 2024, the Company issued to an accredited investor a term note (the “ Note ”) with a principal face amount of $310,000. The Note bears interest at the rate of fifteen percent (15%) per annum and the Note was issued with an original issuance discount. The maturity date of the Note is May 13, 2024.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$310,000"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Rate","value":"fifteen percent (15%) per annum"},{"label":"Maturity","value":"May 13, 2024"},{"label":"Event","value":"incurrence"}]},{"claim_id":"3843345b1c9dd69c0dca44d39dba1516814764a4","claim":"Alzamend Neuro, Inc. entered into the Note with an accredited investor valued at $310,000 (effective 2024-04-29).","evidence_excerpt":"Effective April 29, 2024, the Company issued to an accredited investor a term note (the “ Note ”) with a principal face amount of $310,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"$310,000"},{"label":"Effective","value":"2024-04-29"}]},{"claim_id":"ad3b81327df5c3f45cad26ca0d9e5aeb98824063","claim":"Alzamend Neuro, Inc. entered into the Guaranty with Ault Lending (effective 2024-04-29).","evidence_excerpt":"Ault Lending Additional Closing On April 29, 2024, Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”), pursuant to the Securities Purchase Agreement (the “ Agreement ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Ault Lending"},{"label":"Effective","value":"2024-04-29"}]},{"claim_id":"c41730d33038dc9dc17018046e70f32c998899c8","claim":"Alzamend Neuro, Inc. entered into the Securities Purchase Agreement with Ault Lending, LLC valued at $2.1 million (effective 2024-01-31).","evidence_excerpt":"lzamend Neuro, Inc., a Delaware corporation (the “ Company ”), pursuant to the Securities Purchase Agreement (the “ Agreement ”) entered into with Ault Lending, LLC, a California limited liability company (“ Ault Lending ”) on January 31, 2024, sold","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Ault Lending, LLC"},{"label":"Value","value":"$2.1 million"},{"label":"Effective","value":"2024-01-31"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}